



Global Precision
Medicine Innovator

NGeneBio



NGS Panel_Precision cancer diagnostics products

NGeneBio

Commercialization of precision diagnostics products regarding most cancer types such as breast cancer, blood cancer, and solid cancer.
Currently being **used by both local and overseas clients** through comparative advantages with global products.

BRCAaccuTest™ PLUS



Cancer breast/or ovarian cancer
Specimen Tumor tissue and blood
Gene BRCA 1/2



Key features

- The first CE-IVD registered NGS product in Asia ('17.6)
- The first KFDA approved NGS product ('17.12)
- Complex CNV analysis available (paper by Gangnam St. Mary's Hospital)
- Exported to Europe and Asia
- Used for development of companion diagnostics regarding global 'P' pharma company's PARP-inhibitor

HEMEaccuTest™



Cancer 5 types of blood cancer, including AML
Specimen Blood
Gene More than 100 (53 RNA)



Key features

- The first CE-IVD registered blood cancer NGS product in S.Korea ('18.4Q)
- DNA & RNA panels
- Used for blood cancer NGS big data research (multi site clinical trials)
- Verified superiority through comparative testing with global companies' products by top hospital in Singapore
- Used for development of companion diagnostics and clinical trials with local pharma companies

SOLIDaccuTest™



Cancer Gastric cancer, lung cancer, colon cancer, etc.
Specimen Tumor tissue (FFPE)
Gene More than 80 (30 RNA)



Key features

- The first CE-IVD registered solid tumor NGS product in S.Korea ('20.1Q)
- DNA & RNA panels
- Provided with solid cancer analysis SW
- Used for development of clinical trials with local pharma companies (SOLIDaccuPanel DNA)
- Used for companion diagnostics research of NTRK-targeted treatment (SOLIDaccuTest RNA)

ONCOaccuPanel™



Cancer Gastric cancer, lung cancer, colon cancer, etc.
Specimen Tumor tissue (FFPE)
Gene 344



Key features

- Commercialized panel jointly developed by Asan Medical Center and Dana-Farber Cancer Institute
- Completed clinical tests for over 10,000 tumor specimen
- Completed clinical trial for regulatory approval
- TMB, MSI detection for prediction of immunotherapy effectiveness
- Expanding into companion diagnostics

NGS Panel_Newly launched precision diagnostics products

NGeneBio

Expansion of NGS tests solving the problems of existing limited tests

HLAaccuTest™ All



Purpose	Bone marrow transplant conformity test
Specimen	Blood
Gene	11 loci including HLA-A, B, C, etc.

Key features

- KFDA approved for 5 loci HLA typing ('21.5)
- CE-IVD approved for 11 loci HLA typing ('21.11)
- The first 11 loci HLA typing NGS product in S.Korea
- Provides SW that can automatically assess HLA suitability between donor and patient
- National Health Insurance Service(NHIS) approved for medical insurance in S.Korea
- 3 related patents registered

MTBaccuPanel™



Purpose	TB/NTM test Prediction of anti-drugs resistant Identification & Lineage
Specimen	sputum bronchial washing or culture

Key features

- CE-IVD in May 2022
- Amplicon-based target enrichment NGS
- ~180 Mycobacterial species can be detected
- 29 genes targeted to identify MT species and drug-resistance (DR)
- Identifying DR among up to ~18 antimycobacterial drugs against TB

MRDaccuPanel™ AML FLT3-ITD (on-develop)



Purpose	Minimum Residual Disease test
Specimen	Blood
Target	AML / FLT3-ITD

Key features (Developing)

- Amplicon-based target enrichment NGS
- To track and identify previously detected FLT3-ITD (internal tandem duplication, E14-E15) & TKD (tyrosine kinase domain, E20) mutations in post-treatment follow-up samples
- Monitor ITD & TKD mutations in the FLT3 gene and evaluate for disease recurrence
- Stratifying risk for AML/MDS recurrence
- an allelic sensitivity level (aim for at $<10^{-5}$ with dual UMI application)

MRDaccuPanel™ ctDNA (on-develop)



Purpose	Solid tumor diagnosis Post-treatment monitoring
Specimen	Liquid biopsy

Key features (Developing)

- Progress to the commercialization and clinical trial of integrated Liquid Biopsy Solution
- Cancer prognosis diagnostics: Confirm the progress of cancer and the effectiveness of treatments with blood samples using our existing commercial precision diagnostics panels



NGeneAnalySys® for cancer



BRCAaccuTest™ PLUS



HEMEaccuTest™



SOLIDaccuTest™



ONCOaccuPanel™



EasyHLAanalyzer™ for HLA Typing



HLAaccuTest™ All



Официальный дистрибьютор в Республике Беларусь:
ОДО "ТОСИЛЕНА", УНП 101025038
Беларусь, 220073, г. Минск
Тел.: +375 17 300 8125
Факс: +375 17 300 8126
E-mail: tosilena@tosilena.com
Instagram: [@tosilena.official](https://www.instagram.com/tosilena.official)
Website: www.tosilena.com

